U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
134361
Substance Class Protein
Created
by admin
on Thu Jul 06 18:01:17 UTC 2023
Edited
by admin
on Thu Jul 06 18:01:17 UTC 2023
Protein Type RECEPTOR
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
P6W5IXV8V9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMPA-SELECTIVE GLUTAMATE RECEPTOR 2
Common Name English
AMPAR (GLUR-2)4
Common Name English
GLUR-K2
Common Name English
GLUR-B
Common Name English
GLUA2
Common Name English
GLUR2
Common Name English
GLUR-2
Common Name English
GLUTAMATE RECEPTOR IONOTROPIC, AMPA 2
Common Name English
GLUTAMATE RECEPTOR 2
Common Name English
Code System Code Type Description
FDA UNII
P6W5IXV8V9
Created by admin on Thu Jul 06 18:01:21 UTC 2023 , Edited by admin on Thu Jul 06 18:01:21 UTC 2023
PRIMARY
UNIPROT
P42262
Created by admin on Thu Jul 06 18:01:21 UTC 2023 , Edited by admin on Thu Jul 06 18:01:21 UTC 2023
PRIMARY
PHAROS
P42262
Created by admin on Thu Jul 06 18:01:21 UTC 2023 , Edited by admin on Thu Jul 06 18:01:21 UTC 2023
PRIMARY
From To
1_54 1_306
4_54 4_306
2_54 2_306
3_54 3_306
1_715 1_770
4_715 4_770
2_715 2_770
3_715 3_770
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_232
N 1_346
N 1_382
N 1_389
N 2_232
N 2_346
N 2_382
N 2_389
N 3_232
N 3_346
N 3_382
N 3_389
N 4_232
N 4_346
N 4_382
N 4_389
Related Record Type Details
Structure of GLUTAMIC ACID
AGONIST -> TARGET
The endogenous agonist
Structure of FG-9041
INHIBITOR -> TARGET
Structure of TALAMPANEL
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET
Structure of SELURAMPANEL
INHIBITOR -> TARGET
Structure of KAITOCEPHALIN
INHIBITOR -> TARGET
Structure of PERAMPANEL
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET
Structure of PESAMPATOR
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Structure of FANAPANEL
INHIBITOR -> TARGET
Structure of FARAMPATOR
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
Structure of TULRAMPATOR
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
High-impact AMPAR PAM decreases both deactivation and desensitization together to enhance and prolong synaptic currents.
Structure of OXIRACETAM
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
Structure of IRAMPANEL
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET
Structure of THEANINE
INHIBITOR -> TARGET
Structure of MIBAMPATOR
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
High-impact AMPAR PAM decreases both deactivation and desensitization together to enhance and prolong synaptic currents.
Structure of DASOLAMPANEL
INHIBITOR -> TARGET
Structure of CX-546
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
Structure of CX-1739
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents.
Structure of CYANQUIXALINE
INHIBITOR -> TARGET
Structure of BECAMPANEL
INHIBITOR -> TARGET
Structure of HYDROXYNORKETAMINE, (2R,6R)-
ACTIVATOR -> TARGET
Structure of CYANQUIXALINE
INHIBITOR -> TARGET
Structure of LY-503430
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Structure of PIRACETAM
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
This action is very weak and its clinical effects may not necessarily be mediated by this action.
Structure of IBOTENIC ACID
AGONIST -> TARGET
Structure of ZONAMPANEL ANHYDROUS
INHIBITOR -> TARGET
Structure of MK-8777
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Structure of CX516
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
Structure of DOMOIC ACID
AGONIST -> TARGET
Structure of GYKI-52466
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET
Structure of PRAMIRACETAM
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents.
Structure of KYNURENIC ACID
INHIBITOR -> TARGET
Endogenous ligand
Structure of TEZAMPANEL ANHYDROUS
INHIBITOR -> TARGET
Structure of LY-404187
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
High-impact AMPAR PAM decreases both deactivation and desensitization together to enhance and prolong synaptic currents.
Structure of QUISQUALIC ACID
AGONIST -> TARGET
Structure of AMPA
AGONIST -> TARGET
Structure of CYCLOTHIAZIDE
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Structure of PF-4778574
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Structure of NBQX
INHIBITOR -> TARGET
Structure of L-WILLARDIINE
AGONIST -> TARGET
Structure of ANIRACETAM
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents
Structure of CX-717
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Low-impact AMPAR PAMs decrease AMPAR deactivation (channel closing) alone to augment synaptic currents.
ALLOSTERIC ACTIVATOR
Structure of PEPA
POSITIVE ALLOSTERIC MODULATOR (PAM)->TARGET
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966